| DHR | 5.09% | 204.85 | -0.32% | 0 | |
| ABT | 5.00% | 132.02 | -1.18% | 0 | |
| TMO | 4.96% | 434.86 | +0.96% | 0 | |
| GILD | 4.88% | 109.64 | -4.28% | 0 | |
| BMY | 4.87% | 46.86 | -3.42% | 0 | |
| VRTX | 4.77% | 468.85 | -2.23% | 0 | |
| REGN | 4.60% | 567.74 | +1.43% | 0 | |
| ROG | 4.22% | 256.80 | -2.36% | 0 | |
| MRNA | 3.75% | 33.64 | -1.87% | 0 | |
| ICLR | 3.50% | 150.52 | -1.02% | 0 |
BMO MSCI Genomic Innovation Index ETF is an exchange traded fund launched and managed by BMO Asset Management Inc. It invests in public equity markets of global region. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, innovative genomic companies such as gene editing, agricultural biotechnology, molecular diagnostics, genome related hardware for analytics and diagnostics, bioinformatics, targeted therapeutics, and gene and stem cell therapies sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track the performance of the MSCI ACWI IMI Genomic Innovation Index, by using full replication technique. BMO MSCI Genomic Innovation Index ETF was formed on January 20, 2021 and is domiciled in Canada.